Chardan lowered the firm’s price target on 4D Molecular (FDMT) to $30 from $39 but keeps a Buy rating on the shares following the company’s interim 52-week data from the phase 2b portion of the PRISM trial evaluating 4D-150 in a broad wet AMD patient population.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4D Molecular’s wAMD drug is best-in-class, says RBC, sees ‘ideal’ entry point
- Cautious ‘Hold’ Rating on 4D Molecular Therapeutics Amidst Competitive Market and Investor Concerns
- 4D Molecular Therapeutics: Strong Buy Rating on Promising 4D-150 Gene Therapy Data and Strategic Phase 3 Trials
- Promising Prospects for 4D Molecular Therapeutics: Anticipated Growth in wAMD Treatment and Market Valuation
- 4D Molecular price target lowered to $42 from $46 at BofA